文献速递临床试验与 GCP医学教育与科研方法

探索SCOPE2试验参与者体验的定性研究:食管癌放化疗剂量递增

A qualitative study exploring participants' experiences of the SCOPE2 trial: chemoradiotherapy dose escalation in oesophageal cancer.
PubMed 文献 · Trials · 2025-02-26

本研究为2017至2021年在英国五个临床中心开展的纵向访谈研究,探索不可手术食管癌患者对SCOPE2试验(放化疗剂量递增)的体验与看法。十名参与者接受16次纵向访谈,主题分析显示招募困难,参与动机包括利他、可能获得更好照护与监测及改善生活质量,参与者认为COVID-19对试验体验影响较小但部分治疗延迟。

要点

  • SCOPE2试验中患者参与动机包括利他、可能获得更好照护与监测及改善生活质量。
  • 患者需要充分时间考虑信息并定期获得试验与治疗进展更新。
  • 参与者认为COVID-19对试验体验影响较小,但报告了部分治疗延迟。

核心结论

  • 增加患者与试验人员及第三方合作伙伴讨论并适时获得适当信息的机会,可增强患者对未来试验、治疗和程序的理解。
  • 试验与定性研究招募缓慢,COVID-19大流行进一步阻碍招募,未来试验可从更充分整合的定性招募方法中获益。

研究设计与样本

  • 纵向访谈研究,2017年至2021年间从英国五个临床中心招募符合放化疗条件的患者。
  • 邀请参与者在基线(治疗前)及基线后2-3个月、3-6个月或6个月以上共四个不同时间点参加三次半结构化访谈。
  • 采用主题分析法分析访谈资料,并通过实时报告向试验团队反馈以改进试验实施与招募。

主要发现

  • 十名参与者在16次纵向访谈中接受访谈,其中女性五名、男性五名,三名参与者在访谈中有陪伴者。
  • 试验与定性研究招募具有挑战性。
  • 参与试验的动机包括利他、可能获得更好的照护与监测以及改善生活质量的机会。
  • 参与者需要充分时间考虑信息并定期获得关于试验和治疗过程的更新。
  • 参与者认为其试验体验受COVID-19影响较小,但报告了一些治疗延迟。

局限性

  • 招募至试验与定性研究具有挑战性,COVID-19大流行进一步阻碍了招募。
  • 部分参与者报告了治疗延迟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This qualitative study explored patients' experiences and perceptions of the SCOPE2 trial. The trial studied radiotherapy dose escalation in patients with inoperable oesophageal cancer treated with definitive chemo-radiation. SCOPE2 embedded a phase II trial for patients with a poor early response using positron emission tomography (PET) scans. METHODS: This longitudinal interview study took place between 2017 and 2021. Patients eligible for chemoradiotherapy were recruited from five clinical sites in the UK. Participants were invited to participate in three semi-structured interviews across four different time points: baseline (before treatment) and at 2-3 months, 3-6 months or 6 months + after baseline. This paper focuses on recruitment to the trial, practical management, the impact of COVID-19 and reflections of being on the trial. Real-time reporting to the trial team was used to inform potential improvements to trial conduct and recruitment. The interviews were thematically analysed. RESULTS: Ten participants were interviewed in 16 longitudinal interviews. There were five female and five male interview participants; three participants were accompanied by companions during their interviews. Recruitment to the trial and qualitative study was challenging. Motivations for joining the trial included altruism, potentially receiving better care and monitoring and the opportunity to improve their quality of life. Participants required adequate time to consider information and regular updates regarding trial and treatment process. Participants felt that their trial experience was minimally impacted by COVID-19, although some delays to treatment were reported. CONCLUSION: Increased opportunities for patients to discuss and receive appropriate and timely information from trial staff and third sector partners could enhance patients' understanding of future trials, treatments and procedures. Slow recruitment to the trial and qualitative study was further impeded by the COVID-19 pandemic and future trials would benefit from a more fully integrated approach to qualitative recruitment. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT02741856 registered on 12 April 2016; ISRCTN: 9,712,546 registered on 26 October 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Holland-Hart D, Longo M, Bridges S, et al. A qualitative study exploring participants' experiences of the SCOPE2 trial: chemoradiotherapy dose escalation in oesophageal cancer. Trials. 2025. PMID: 40012034. doi:10.1186/s13063-025-08768-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。